Lundbeck presents positive results from migraine drug trial
New data from a study of Lundbeck's migraine drug Vyepti shows a significant effect on patients who have been through two to four prior failed treatments with other types of migraine drugs.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED DANIEL PEDERSEN
Both primary and secondary endpoints were met in Lundbeck's phase IIIb trial, which goes under the name Deliver, of the migraine drug Vyepti, it reports in a press release on Monday morning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck chairman demands change: "We can't live with this"
For subscribers
Lundbeck CEO considers stepping up marketing of Vyepti
For subscribers
.jpg&w=384&q=75)
